Literature DB >> 29516344

A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.

Makoto Ideguchi1, Takafumi Nishizaki2, Norio Ikeda2, Tomomi Okamura2, Yasue Tanaka2, Natsumi Fujii2, Machiko Ohno2, Taichi Shimabukuro2, Tokuhiro Kimura3, Eiji Ikeda3, Kazuyoshi Suga4.   

Abstract

The objective of this study was to investigate the distribution of 11C-methionine (MET) and F-18 fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) imaging and the hyperintense area in T2 weighted imaging (T2WI) in glioma with no or poor gadolinium enhancement in magnetic resonance imaging (GdMRI). Cases were also analyzed pathologically. We prospectively investigated 16 patients with non- or minimally enhancing (< 10% volume) glioma. All patients underwent MET-PET and FDG-PET scans preoperatively. After delineating the tumor based on MET uptake, integrated 3D images from FDG-PET and MRI (GdMRI, T2WI or FLAIR) were generated and the final resection plane was planned. This resection plane was determined intraoperatively using the navigation-guided fencepost method. The delineation obtained by MET-PET imaging was larger than that with GdMRI in all cases with an enhanced effect. In contrast, the T2WI-abnormal signal area (T2WI+) tended to be larger than the MET uptake area (MET+). Tumor resection was > 95% in the non-eloquent area in 4/5 cases (80%), whereas 10 of 11 cases (90.9%) had partial resection in the eloquent area. In a case including the language area, 92% resection was achieved based on the MET-uptake area, in contrast to T2WI-based partial resection (65%), because the T2WI+/MET- area defined the language area. Pathological findings showed that the T2WI+/MET+ area is glioma, whereas 6 of 9 T2WI+/MET- lesions included normal tissues. Tissue from T2W1+/MET+/FDG+/GdMRI+ lesions gave an accurate diagnosis of grade in six cases. Non- or minimally enhancing gliomas were classified as having a MET uptake area that totally or partially overlapped with the T2WI hyperintense area. Resection planning with or without a metabolically active area in non- or minimally enhancing gliomas may be useful for accurate diagnosis, malignancy grading, and particularly for eloquent area although further study is needed to analyze the T2WI+/MET- area.

Entities:  

Keywords:  11C-methionine PET; F-18 fluorodeoxyglucose PET; Fence-post method; Non- or minimally enhancing glioma; Tumor delineation

Mesh:

Substances:

Year:  2018        PMID: 29516344     DOI: 10.1007/s11060-018-2821-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  48 in total

1.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas.

Authors:  S-A Yeh; J-T Ho; C-C Lui; Y-J Huang; C-Y Hsiung; E-Y Huang
Journal:  Br J Radiol       Date:  2005-03       Impact factor: 3.039

3.  Use of neuronavigation and electrophysiology in surgery of subcortically located lesions in the sensorimotor strip.

Authors:  W Eisner; J Burtscher; R Bale; R Sweeney; F Koppelstätter; S Golaszewski; C Kolbitsch; K Twerdy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

4.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

5.  Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults.

Authors:  Kaisorn L Chaichana; Thomas Kosztowski; Ashwini Niranjan; Alessandro Olivi; Jon D Weingart; John Laterra; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

6.  Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.

Authors:  A Pace; A Vidiri; E Galiè; M Carosi; S Telera; A M Cianciulli; P Canalini; D Giannarelli; B Jandolo; C M Carapella
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

7.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

Review 8.  Advances in evaluation of primary brain tumors.

Authors:  Wei Chen; Daniel H S Silverman
Journal:  Semin Nucl Med       Date:  2008-07       Impact factor: 4.446

9.  Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study.

Authors:  K Herholz; U Pietrzyk; J Voges; R Schröder; M Halber; H Treuer; V Sturm; W D Heiss
Journal:  J Neurosurg       Date:  1993-12       Impact factor: 5.115

10.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

View more
  4 in total

1.  18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Authors:  Chirag B Patel; Elisa Fazzari; Ararat Chakhoyan; Jingwen Yao; Catalina Raymond; Huytram Nguyen; Jasmine Manoukian; Nhung Nguyen; Whitney Pope; Timothy F Cloughesy; Phioanh L Nghiemphu; Johannes Czernin; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-04-20       Impact factor: 4.130

2.  18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.

Authors:  Ziren Kong; Yusong Lin; Chendan Jiang; Longfei Li; Zehua Liu; Yuekun Wang; Congxin Dai; Delin Liu; Xuying Qin; Yu Wang; Zhenyu Liu; Xin Cheng; Jie Tian; Wenbin Ma
Journal:  Cancer Imaging       Date:  2019-08-19       Impact factor: 3.909

Review 3.  Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Authors:  Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

4.  A Non-invasive Radiomic Method Using 18F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma.

Authors:  Longfei Li; Wei Mu; Yaning Wang; Zhenyu Liu; Zehua Liu; Yu Wang; Wenbin Ma; Ziren Kong; Shuo Wang; Xuezhi Zhou; Wei Wei; Xin Cheng; Yusong Lin; Jie Tian
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.